IL-SHIPPEO
8.4.2024 17:01:33 CEST | Business Wire | Press release
Yamaha Motor Co., Ltd. (Yamaha Japan) and its U.S. subsidiary, Yamaha Motor Corporation, USA (Yamaha USA), today announced a strategic partnership with Shippeo, a leading provider of real-time transportation visibility solutions. Shippeo will provide Yamaha with superior visibility and predictive insights across its entire global supply chain, encompassing ocean, railroad and over the road transportation.
Enhanced Visibility Across the Supply Chain
Yamaha Japan will leverage Shippeo's global network to gain complete coverage of all ocean containers transporting its goods. This includes real-time visibility into all ocean carriers, terminals, ports, and ships, along with predictive arrival estimates. Shippeo's platform ingests data from various sources, including ocean carriers, satellite providers, schedules, and its own proprietary data models, to create a unified and comprehensive view of all shipments.
Seamless Integration and Actionable Insights
Shippeo's solution seamlessly integrates with Yamaha's existing systems, providing both a web-based application and data transmission into Yamaha's SAP solutions. Additionally, Shippeo offers a suite of readily available and configurable business intelligence reports, enabling Yamaha to gain valuable insights across various aspects of their supply chain.
Tangible Value for Yamaha
By partnering with Shippeo, Yamaha expects to achieve significant benefits, including:
Superior customer experience: Enhanced transparency and reliability through real-time visibility and arrival predictions for Yamaha customers, partners, and dealers.
- Improved operational efficiency: Optimized lead time management, warehouse management, and personnel productivity.
- Enhanced cost control: Reduced freight spend and related costs through better visibility and proactive management of detention, demurrage, and accessorial fees.
- Improved transportation vendor management: Data-driven insights to optimize carrier selection and performance based on key metrics like on-time delivery and shipment accuracy.
“We are truly excited about this new strategic partnership with Shippeo and the benefits that it will most certainly bring to easing our Global Supply Chain challenges, simply from providing more seamless administrative and global visibility, “said Isamu “Sam” Kuru of Yamaha Motor Company Japan’s logistics Division. “The benefits to both our distributors and ultimately our Yamaha dealerships and business to business partners and end users will prove invaluable to our entire company.”
"It's an honor to partner with an industry pioneer like Yamaha Motor Company," said Christopher Mazza, SVP International Growth at Shippeo. "Our leading real-time visibility solution empowers Yamaha to deliver exceptional value to their customers and end users by offering superior visibility and actionable insights across all transport modes. This will enhance the resilience of Yamaha's global supply chain operations, ensuring enhanced transparency and reliability."
About Yamaha Motor Corporation, USA
Yamaha Motor Corporation, USA (YMUS), is a recognized leader in the outdoor recreation industry. The company's ever-expanding product offerings include Motorcycles and Scooters, ATV and Side-by-Side vehicles, Snowmobiles, WaveRunner Personal Watercraft, Boats, Outboard Motors, Outdoor Power Equipment, Power Assist Bicycles, Golf Cars, Power Assist Wheelchair Systems, Surface Mount Technology (SMT) and Robotic Machines, Unmanned Helicopters, Accessories, Apparel, Yamalube products, and much more. YMUS products are sold through a nationwide network of distributors and dealers in the United States.
YMUS has a corporate office in California, two corporate offices in Georgia, facilities in Wisconsin and Alabama, and factory operations in Tennessee and Georgia. Additional U.S.-based subsidiaries include Yamaha Marine Systems Company (YMSC) with divisions Bennett Marine (Florida), Kracor Systems (Wisconsin) and Siren Marine, Inc. (Rhode Island), Skeeter Boats (Texas), with division G3 Boats (Missouri), and Yamaha Precision Propeller (Indiana).
About Shippeo
Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more resilient, sustainable, and customer-centric supply chains. This is made possible with highly accurate real-time operational visibility and Transport Process Automation™ to streamline transportation processes, reduce latency and improve operational efficiency. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and GHG emissions from supply chain transport.
Hundreds of customers, including global brands like Ahold Delhaize, AkzoNobel, Amazon, Avery Dennison, Arlanxeo, Barilla, Birra Peroni, Bosch Siemens Hausgeräte, Carrefour, Coca-Cola HBC, DP World, Evonik, Fujifilm, Jaguar Land Rover, Hartmann Group, Heineken, Kuehne+Nagel, L’Oréal, LVMH, Renault Group, Sabic, Saint-Gobain, XPO Logistics and Yamaha Motor, trust Shippeo to track more than 50 million shipments per year across 130 countries. Learn more at www.shippeo.com, LinkedIn, Facebook, X (formerly Twitter)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408354099/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
